Systemic Antiviral Therapy for Active Herpes Simplex Lesions
For first-episode genital herpes in immunocompetent adults, treat with acyclovir 400 mg orally three times daily for 5 days, or acyclovir 200 mg orally five times daily for 5 days, or acyclovir 800 mg orally twice daily for 5 days; for recurrent episodes, the same regimens apply but treatment benefit is greatest when started within 1 day of lesion onset. 1
Treatment Approach by Clinical Scenario
First Clinical Episode of Genital Herpes
The 1998 CDC guidelines provide the most recent comprehensive recommendations among the guideline evidence. For initial genital herpes episodes, multiple acyclovir dosing regimens are equally effective 1:
- Acyclovir 400 mg orally 3 times daily for 5 days, OR
- Acyclovir 200 mg orally 5 times daily for 5 days, OR
- Acyclovir 800 mg orally twice daily for 5 days
Alternative agents with comparable efficacy include 1:
- Famciclovir 125 mg orally twice daily for 5 days
- Valacyclovir 500 mg orally twice daily for 5 days
The newer agents (valacyclovir and famciclovir) offer improved dosing convenience, which enhances adherence for prolonged treatment 1.
Recurrent Episodes
Critical timing consideration: Treatment must be initiated during prodrome or within 1 day of lesion onset to achieve meaningful clinical benefit 1. The same dosing regimens apply as for first episodes, but the clinical impact is more modest given the self-limited nature of recurrences.
Most immunocompetent patients with recurrent disease experience only limited benefit from episodic therapy because early treatment is rarely feasible 2. However, patients who can reliably recognize prodromal symptoms and initiate therapy immediately may benefit 1.
Oral Herpes (Herpes Labialis)
For recurrent oral HSV in immunocompetent adults 3:
- Acyclovir 400 mg orally 3 times daily for 3-5 days, OR
- Valacyclovir 500-1000 mg orally twice daily for 3-5 days
Topical acyclovir 5% cream may reduce lesion duration if applied very early, but systemic therapy is more effective 3, 4.
Suppressive Therapy for Frequent Recurrences
For patients with ≥6 recurrences per year, daily suppressive therapy reduces recurrence frequency by ≥75% 1:
- Acyclovir 400 mg orally twice daily, OR
- Famciclovir 250 mg orally twice daily, OR
- Valacyclovir 250-500 mg orally twice daily, OR
- Valacyclovir 1000 mg orally once daily
Important caveat: Valacyclovir 500 mg once daily is less effective in patients with ≥10 episodes per year 1.
Safety has been documented for acyclovir use up to 6 years and for valacyclovir/famciclovir for 1 year 1. After 1 year of continuous suppression, discontinue therapy to reassess recurrence rate, as frequency naturally decreases over time in many patients 1.
Severe Disease Requiring Hospitalization
For disseminated infection, encephalitis, pneumonitis, hepatitis, or meningitis 2, 1:
Acyclovir 5-10 mg/kg IV every 8 hours for 5-7 days or until clinical resolution
Key Clinical Pitfalls
Topical therapy is substantially less effective than oral treatment and should be avoided 2. The evidence consistently shows topical acyclovir has minimal clinical benefit compared to systemic therapy.
Timing is everything for episodic treatment: The window for effective intervention is narrow—treatment started >1 day after lesion onset provides minimal benefit 1. Patients should be provided with medication or a prescription in advance to enable immediate self-initiation at first prodromal symptoms.
Suppressive therapy does not eliminate transmission risk: While it reduces asymptomatic viral shedding, it does not completely prevent it 1. Patients must understand that transmission can still occur even on suppressive therapy.
Resistance concerns: Acyclovir-resistant strains have been isolated during suppressive therapy but have not been associated with treatment failure in immunocompetent patients 1. Resistance is primarily a concern in immunocompromised hosts requiring alternative agents like foscarnet 5.
Evidence Quality Considerations
The most recent guideline evidence is from 1998 1, which introduced famciclovir and valacyclovir as alternatives to acyclovir. While older, these CDC guidelines represent the highest-quality systematic recommendations available. The 2022 CDC review 6 confirms these approaches remain current standard of care. Recent research 7, 8 supports the continued use of these regimens without substantive changes to the core treatment algorithms.